Dr. New is Professor, Residency Training Director and Vice Chair for Education in the Department of Psychiatry at Mount Sinai. Dr. New has a longstanding career as a funded principal investigator studying the neurobiology of borderline personality disorder. Her research focus is on emotion dysregulation and emotional interoception abnormalities in borderline personality disorder, symptom domains which underlie some of the interpersonal difficulties encountered in this disorder. In addition, Dr. New explores individual differences in response to stress and trauma, focusing on how this relates to emotion regulation. She uses brain imaging techniques, genetic studies, and laboratory assessment of behavior to explore neural circuitry and mechanisms of treatment response in BPD. In addition, Dr. New has been a teacher and mentor to medical students, residents and post-doctoral fellows throughout her career. She was Director of Medical Student Education in the Department of Psychiatry at The Icahn School of Medicine at Mount Sinai prior to rising to the position of Residency Training Director and Vice Chair for Education. Dr. New has won several awards for teaching and scholarship. She completed her residency in psychiatry at New York Hospital/ Payne Whitney Clinic and a postdoctoral research fellowship at Mount Sinai. She received her medical degree from Cornell University School of Medicine.
Financial & Billing Information
Please direct any detailed billing or financial inquires to the Mount Sinai Psychiatry billing customer service number at 212-659-8752.
MD, Cornell University Medical College
Residency, Internal Medicine
New York Hospital - Cornell Medical Center
Payne Whitney Clinic
Mount Sinai Hospital
Psychiatry, American Board of Psychiatry and Neurology
New as, Triebwasser j, Charney ds. The Case for Shifting Borderline Personality Disorder to Axis I. Biol Psychiatry 2008 Jun 10; [Epub ahead of print].
New as, Goodman m, Triebwasser j, Siever lj. Recent advances in the biological study of personality disorders. Psychiatr Clin North Am 2008 Sept; 31(3).
Minzenberg mj, Fan j, New as, Tang cy, Siever lj. Frontolimbic structural changes in borderline personality disorder. J Psychiatr Res 2008; 42(9).
Minzenberg mj, Fan j, New as, Tang cy, Siever lj. Frontolimbic dysfunction in response to facial emotion in borderline personality disorder: an event-related fMRI study. Psychiatry Res 2007 Aug 15; 155(3).
Hazlett ea, Speiser lj, Goodman m, Roy m, Carrizal m, Wynn jk, Williams wc, Romero m, Minzenberg mj, Siever lj, New as. Exaggerated Affect-Modulated Startle During Unpleasant Stimuli in Borderline Personality Disorder. Biological Psychiatry 2007; 62(3).
New as, Hazlett ea, Buchsbaum ms, Goodman m, Mitelman sa, Newmark r, Trisdorfer r, Haznedar mm, Koenigsberg hw, Flory j, Siever lj. Amygdala-Prefrontal Disconnection in Borderline Personality Disorder. Neuropsychopharmacology 2007; 32(7).
Hazlett ea, New as, Newmark r, Haznedar mm, Lo jn, Speiser lj, Chen ad, Mitropoulou v, Minzenberg m, Siever lj, Buchsbaum ms. Reduced Anterior and Posterior Cingulate Gray Matter in Borderline Personality Disorder. Biol Psychiatry 2005 Oct 15; 58(8).
New as, Buchsbaum ms, Hazlett ea, Goodman m, Koenigsberg hw, Lo j, Iskander l, Newmark r, Brand j, O'Flynn k, Siever lj. Fluoxetine increases relative metabolic rate in prefrontal cortex in impulsive aggression. Psychopharmacology (Berl) 2004 Nov; 176(3-4).
New as, Hazlett ea, Buchsbaum ms, Goodman m, Reynolds d, Mitropoulou v, Sprung l, Shaw rb, Koenigsberg h, Platholi j, Silverman j, Siever lj. Blunted prefrontal cortical FDG-PET response to meta-chlorophenylpiperazine in impulsive aggression. Arch Gen Psychiatry 2002; 59(7).
New as, Gelernter j, Goodman m, Mitropoulou v, Koenigsberg hw, Silverman jm, Siever lj. Suicide, impulsive aggression and HTR1B genotype. Biol Psychiatry 2001; 50(1).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.New did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.